NCT05306847View on ClinicalTrials.gov

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

April 1, 2024

Study Completion Date

April 1, 2026

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Sintilimab

Sintilimab will be given intravenously at a dose of 200mg every 21 days.

DRUG

Anlotinib

Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.

Sponsors
All Listed Sponsors
collaborator

Xinda Biopharmaceutical Group

UNKNOWN

collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Peking Union Medical College Hospital

OTHER